---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014768"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:54.483730+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M

## Summary
- Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.
- Operating loss of $4.1 million for Q3 2024 versus $3.5 million in Q3 2023; net loss of $3.8 million ($0.64 per share).
- Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 shows well-tolerated profile with no unexpected toxicities at subtherapeutic doses.
- Phase 1/2a ABOYA-119 trial of ATR inhibitor ATRN-119 enrolling at dose level 6 (800 mg QD); twice-daily dosing added to protocol.
- Engaged Philippe Pultar, MD as senior medical advisor in October 2024 to support APR-1051 development.

## SEC filing metadata
- accession: 0001558370-24-014768
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/0001558370-24-014768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/apre-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014768
- JSON: https://secwatch.observer/filing/0001558370-24-014768.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.